Work Here?
United States Drug Testing
Work Here?
Specialized toxicology drug screening services
United States Drug Testing
Work Here?
Specialized toxicology drug screening services
Overview
USDTL provides toxicology testing services using advanced drug screening in hair, nail, and umbilical cord tissue for healthcare providers, legal entities, and research institutions. Clients submit samples and USDTL runs panel-based analyses, delivering results with interpretations. They differentiate themselves by using matrices beyond blood or urine and by offering customized testing panels. Their goal is to be a leading provider of fast, precise, and reliable drug-screening across multiple specimen types.
About United States Drug Testing
Industries
Data & Analytics
Government & Public Sector
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Des Plaines, Illinois
Founded
1991
Get referred to United States Drug Testing
See people who can refer or advise you
Simplify's Take
What believers are saying
- Northlane Capital’s January 2025 investment funds expansion and professionalizes governance.
- USDTL’s May 2025 xylazine and psilocin launch captures emerging drug-trend demand immediately.
- The January 2026 Chicago facility plan increases capacity and supports faster turnaround for hospital accounts.
What critics are saying
- Ratfield v. USDTL survived until 7th Circuit dismissal, but reputation damage persists through 2026.
- New York blocks medetomidine, tianeptine, and phenibut in umbilical cord testing, limiting menu reach.
- Northlane integration and Chicago lab buildout raise execution risk; service failures would hit referrals fast.
What makes United States Drug Testing unique
- USDTL’s March 2025 menus cover hair, nail, meconium, and umbilical cord specimens.
- USDTL uniquely adds fentanyl, kratom, gabapentin, xylazine, and tianeptine detection in niche panels.
- USDTL’s January 2026 clinical testing launch broadens forensic expertise into adjacent regulated diagnostics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Paid Vacation
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Brown Gibbons Lang & Company (BGL) announced the sale of United States Drug Testing Laboratories (USDTL) to Northlane Capital Partners (NCP). BGL acted as the exclusive financial advisor for the transaction, with terms undisclosed. USDTL, based in Des Plaines, Illinois, provides alcohol and substance testing services. The partnership with NCP aims to enhance USDTL's testing capabilities and expand its customer base.
Northlane Capital Partners (NCP) has invested in United States Drug Testing Laboratories Inc. (USDTL), a forensic toxicology lab. NCP joins USDTL's founders, Veronica and Doug Lewis, as the first institutional partner. Albert Berger is appointed CEO to lead expansion. NCP aims to leverage its expertise to support USDTL's growth. NCP, based in Bethesda, MD, has invested over $1.7 billion in healthcare and business services sectors.
USDTL has also appointed Albert Berger as Chief Executive Officer to lead the next phase of the company's expansion.
United States Drug Testing is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About United States Drug Testing
Industries
Data & Analytics
Government & Public Sector
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Des Plaines, Illinois
Founded
1991
United States Drug Testing is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today